fbpx
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

View All News
September 28, 2020

Scout Bio to Present at Upcoming October Investor Conferences

PHILADELPHIA, September 28, 2020Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Chief Executive Officer, will present at two upcoming investor conferences.

  • Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1, 2020 at 4:00 p.m. ET
  • Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 2:00 p.m. ET

About Scout Bio

Scout Bio is a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic pet health conditions. Scout has an exclusive research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, which is a global leader in gene therapy research and development for nearly three decades. Scout’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio is ​a private company headquartered in Philadelphia, Pennsylvania. For more information, please visit www.scoutbio.co.

For further information, please contact:

 Investors:

Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
sarah.mccabe@sternir.com

Media:

Fran Gaconnier
Scout Bio
214.417.4142
fran.gaconnier@scoutbio.co

  • News

Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes

Two pilot studies initiated to explore clinical applications for this convenient, one-time injectable treatment Positions Scout Bio as the first company to advance novel GLP-1 constructs for gene therapy…

  • News

Scout Bio Reports Statistically Significant Clinical Outcomes for Pilot Study of SB-001 for Treatment of CKD-Associated Anemia in Felines

SB-001, a gene therapy expressing feline erythropoietin (fEPO), demonstrates clinically relevant hematocrit improvements in end-stage anemia patients and improved quality of life scores PHILADELPHIA, Sept. 30, 2020 (GLOBE NEWSWIRE)…

  • News

Scout Bio Appoints Clinical Research Leader Dr. Anne Traas as Chief Development Officer

PHILADELPHIA, October 28, 2019 – Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, today…